<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Leucovorin: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Leucovorin: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Leucovorin: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9548" href="/d/html/9548.html" rel="external">see "Leucovorin: Drug information"</a> and <a class="drug drug_patient" data-topicid="10795" href="/d/html/10795.html" rel="external">see "Leucovorin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52867341"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Lederle Leucovorin;</li>
<li>MINT-Leucovorin;</li>
<li>RIVA Leucovorin</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1059685"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Methotrexate</span>;</li>
<li>
<span class="list-set-name">Folic Acid Derivative</span></li></ul></div>
<div class="block don drugH1Div" id="F53462487"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing in neonates presented in mg, and mg/kg; use caution. May consider parenteral administration instead of oral in patients with GI toxicity, nausea, vomiting, or who may be unreliable with the precisely timed administration (eg, infants and young children) needed for some indications.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7e1d24b9-2af4-473c-8a84-5ce2e1f23e5c">Folinic acid-responsive seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Folinic acid-responsive seizures:</b> Very limited data available. <b>Note:</b> Folinic acid supplementation may have a potential benefit as an add-on treatment in neonates, especially in the presence of incomplete pyridoxine responsiveness or breakthrough seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Oral: Initial: 1.5 mg/kg/day; may gradually increase up to 3 to 5 mg/kg/day. Dosing based on expert clinical experience and a case report in a neonate with refractory seizures who was on multiple antiseizure medications with pyridoxine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Eichenwald.1','lexi-content-ref-19142996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Eichenwald.1','lexi-content-ref-19142996'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7c1326f-fcc9-4181-a32f-3f8ed7e2fa0a">Pyrimethamine hematologic toxicity, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pyrimethamine hematologic toxicity, prevention (Congenital toxoplasmosis): Note:</b> Leucovorin is administered in combination with pyrimethamine and sulfadiazine in the treatment of congenital toxoplasmosis; leucovorin should continue for 1 week after pyrimethamine is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">HIV-exposed/-infected: IM, Oral: 10 mg with every pyrimethamine dose; treatment duration: 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Non-HIV-exposed/-infected: IM, Oral: 10 mg 3 times weekly for 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.1','lexi-content-ref-18227714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.1','lexi-content-ref-18227714'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F187385"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dosing in pediatric patients presented in mg, mg/m<sup>2</sup> and mg/kg; use caution. Because oral absorption is saturable at doses &gt;25 mg, administration of single oral doses &gt;25 mg is not recommended (convert to parenteral therapy). Also consider parenteral administration instead of oral in patients with GI toxicity, nausea, vomiting, or who may be unreliable with the precisely timed administration (eg, infants and young children) needed for some indications.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a7680f1-cfa5-4ebe-a8d7-51fb3456e23e">Cerebral folate deficiency; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cerebral folate deficiency; treatment:</b> Limited data available: Children and Adolescents: Oral: Initial: 0.5 to 1 mg/kg/day; titrate in 0.5 mg/kg/day increments at monthly intervals based on 5-methyltetrahydrofolate (5MTHF) levels in the cerebrospinal fluid (CSF); doses up to 2 to 3 mg/kg/day may be required. (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25274592','lexi-content-ref-12571785','lexi-content-ref-15581159']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25274592','lexi-content-ref-12571785','lexi-content-ref-15581159'])">Ref</a></span>). Daily doses of 15 to 30 mg have been reported in adolescent patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15781200','lexi-content-ref-12571785']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15781200','lexi-content-ref-12571785'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c29ec35b-1807-443e-8dde-8a015329e49e">Folic acid antagonist overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Folic acid antagonist (eg, pyrimethamine, trimethoprim) overdose:</b> Infants, Children, and Adolescents: Oral: 5 to 15 mg daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c159ec99-68f3-4671-bbc8-99ce4ad56e68">Folinic-acid responsive seizures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Folinic-acid responsive seizures:</b> Very limited data available: Infants and Children: Oral: Initial: 2.5 to 5 mg twice daily; may gradually increase for seizure recurrence; doses up to 8 mg/kg/day (eg, 25 mg 3 times daily) have been reported. Dosing based on small case series and case reports in patients with refractory seizures who were on multiple antiseizure medications with or without pyridoxine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18021918','lexi-content-ref-Eichenwald.1','lexi-content-ref-13677584','lexi-content-ref-19142996','lexi-content-ref-7564240','lexi-content-ref-16458834','lexi-content-ref-10456764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18021918','lexi-content-ref-Eichenwald.1','lexi-content-ref-13677584','lexi-content-ref-19142996','lexi-content-ref-7564240','lexi-content-ref-16458834','lexi-content-ref-10456764'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="21397077-cddf-42ec-b9fd-fad954778403">Megaloblastic anemia secondary to folate deficiency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Megaloblastic anemia secondary to folate deficiency:</b> Infants, Children, and Adolescents: IM, IV: ≤1 mg/day; <b>Note</b>: Although an FDA-approved indication, folic acid is generally used to treat folate deficiency due to inadequate intake (eg, dietary, increased requirements) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24942828','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24942828','lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="17412a28-44b8-40ad-b55b-b40903ba4c94">Methotrexate rescue, high-dose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methotrexate rescue, high-dose: Note: </b> Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; when administering glucarpidase concomitantly with leucovorin calcium, administer leucovorin calcium ≥2 hours before or 2 hours after the glucarpidase dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29079637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29079637'])">Ref</a></span>). Do not administer leucovorin intrathecally; the use of intrathecal leucovorin is not advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8689347','lexi-content-ref-18570175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8689347','lexi-content-ref-18570175'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Dosing regimens variable, refer to specific protocols. Manufacturer labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: Oral, IM, IV: 15 mg (~10 mg/m<sup>2</sup>) every 6 hours; start 24 hours after beginning of methotrexate infusion (based on a methotrexate dose of 12 to 15 <b>g</b>/m<sup>2</sup> IV over 4 hours). Leucovorin (and hydration and urinary alkalinization) should be continued and/or adjusted until the methotrexate level is &lt;0.05 micromolar (5 x 10<sup>-8</sup> M); the manufacturer labeling suggests 10 doses; although some patients may require more. Adjust dose as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Normal methotrexate elimination (serum methotrexate level ~10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and &lt;0.2 micromolar at 72 hours):</i> Oral, IM, IV: 15 mg every 6 hours for 10 doses beginning 24 hours after the start of methotrexate infusion.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Delayed late methotrexate elimination (serum methotrexate level remaining &gt;0.2 micromolar at 72 hours and &gt;0.05 micromolar at 96 hours after administration):</i> Oral, IM, IV: Continue leucovorin calcium 15 mg every 6 hours until methotrexate level is &lt;0.05 micromolar.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Delayed early methotrexate elimination and/or acute renal injury (serum methotrexate level ≥50 micromolar at 24 hours, or ≥5 micromolar at 48 hours, or a doubling of serum creatinine level at 24 hours after methotrexate administration):</i> IV: 150 mg every 3 hours until methotrexate level is &lt;1 micromolar, then 15 mg every 3 hours until methotrexate level is &lt;0.05 micromolar.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e20d6e4b-c4b0-4ac9-9fda-276800468005">Methotrexate overexposure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methotrexate overexposure (high dose):</b> Limited data available:<b> Note: </b>Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; when administering glucarpidase concomitantly with leucovorin calcium, administer leucovorin calcium ≥2 hours before or 2 hours after the glucarpidase dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29079637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29079637'])">Ref</a></span>). Do not administer leucovorin intrathecally; the use of intrathecal leucovorin is not advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8689347','lexi-content-ref-18570175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8689347','lexi-content-ref-18570175'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Leucovorin nomogram dosing for high-dose methotrexate overexposure (generalized dosing derived from reference nomogram figures, refer to each reference (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-342086','lexi-content-ref-Bleyer.1','lexi-content-ref-16794248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-342086','lexi-content-ref-Bleyer.1','lexi-content-ref-16794248'])">Ref</a></span>) or protocol-specific nomogram for details):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>At 24 hours:</b></p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ≥100 micromolar at ~24 hours, leucovorin is initially dosed at 1,000 mg/m<sup>2</sup> IV every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ≥10 to &lt;100 micromolar at 24 hours, leucovorin is initially dosed at 100 mg/m<sup>2</sup> IV every 3 or 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ~1 to 10 micromolar at 24 hours, leucovorin is initially dosed at 10 mg/m<sup>2</sup> IV or orally every 3 or 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>At 48 hours:</b></p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ≥100 micromolar at 48 hours, leucovorin is dosed at 1,000 mg/m<sup>2</sup> IV every 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ≥10 to &lt;100 micromolar at 48 hours, leucovorin is dosed at 100 mg/m<sup>2</sup> IV every 3 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ~1 to 10 micromolar at 48 hours, leucovorin is dosed at 100 mg/m<sup>2</sup> IV every 6 hours <b>or</b> 10 mg/m<sup>2</sup> IV or orally to 100 mg/m<sup>2</sup> IV every 3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>At 72 hours:</b></p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ≥10 micromolar at 72 hours, leucovorin is dosed at 100 to 1,000 mg/m<sup>2</sup> IV every 3 to 6 hours</p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ~1 to 10 micromolar at 72 hours, leucovorin is dosed at 10 mg/m<sup>2</sup> IV or orally to 100 mg/m<sup>2</sup> IV every 3 hours</p>
<p style="text-indent:-2em;margin-left:8em;">For methotrexate levels of ~0.1 to 1 micromolar at 72 hours, leucovorin is dosed at 10 mg/m<sup>2</sup> IV or orally every 3 to 6 hours</p>
<p style="text-indent:-2em;margin-left:6em;">If serum creatinine is increased more than 50% above baseline, increase the standard leucovorin dose to 100 mg/m<sup>2</sup> IV every 3 hours, then adjust according to methotrexate levels above.</p>
<p style="text-indent:-2em;margin-left:6em;">Follow methotrexate levels daily, leucovorin may be discontinued when methotrexate level is &lt;0.1 micromolar; some have suggested &lt;0.08 micromolar (8 x 10<sup>-8</sup> M) is preferable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-342086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-342086'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="471477f7-402e-47c2-8b5d-09717e47ddfe">Methotrexate overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methotrexate overdose (inadvertent): </b>
<b>Note:</b> For oncology patients, refer to protocol-specific nomograms for dosing. Manufacturer labeling:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral, IM, IV: 10 mg/m<sup>2</sup>/dose every 6 hours until the methotrexate level is &lt;0.01 micromolar begin as soon as possible after overdose. If serum creatinine is increased more than 50% above baseline 24 hours after methotrexate administration, if 24-hour methotrexate level is &gt;5 micromolar, or if 48-hour methotrexate level is &gt;0.9 micromolar, increase leucovorin dose to 100 mg/m<sup>2</sup> IV every 3 hours until the methotrexate level is &lt;0.01 micromolar.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Do not administer leucovorin intrathecally; use of intrathecal leucovorin is not advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8689347','lexi-content-ref-18570175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8689347','lexi-content-ref-18570175'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7c1326f-fcc9-4181-a32f-3f8ed7e2fa0a">Pyrimethamine hematologic toxicity, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pyrimethamine hematologic toxicity, prevention: Note:</b> Leucovorin is administered in combination with pyrimethamine and other medications in the treatment of various infections (eg, toxoplasmosis, <i>Pneumocystis jirovecii</i> pneumonia (PCP), cystoisosporiasis); dosing varies with disease process and regimen; consult pyrimethamine specific monograph for additional details; duration of therapy varies based on disease state; however, leucovorin should typically continue for 1 week after pyrimethamine is discontinued (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>); consultant specific guidelines; usual regimens include:</p>
<p style="text-indent:-2em;margin-left:4em;">Toxoplasmosis (<i>Toxoplasma gondii</i>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Congenital toxoplasmosis: Infants:</p>
<p style="text-indent:-2em;margin-left:10em;">HIV-exposed/-infected: IM, Oral: 10 mg with every pyrimethamine dose; treatment duration: 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Non-HIV-exposed/-infected: IM, Oral: 10 mg 3 times weekly for 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18227714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18227714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Acquired infection:</p>
<p style="text-indent:-2em;margin-left:10em;">HIV-exposed/-infected: Infants, Children, and Adolescents: Acute induction: Oral: 10 to 25 mg once daily for ≥6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1','lexi-content-ref-HHS.2'])">Ref</a></span>). <b>Note:</b> In adolescents, leucovorin may be increased to 50 to100 mg/day in divided doses (twice-daily doses) in cases of pyrimethamine toxicity (rash, nausea, bone marrow suppression) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Non-HIV-exposed/-infected: Chorioretinitis: Infants, Children, and Adolescents: Oral: 10 to 20 mg three times weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18227714']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18227714'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Primary:</p>
<p style="text-indent:-2em;margin-left:10em;">HIV-exposed/-infected:</p>
<p style="text-indent:-2em;margin-left:12em;">Infants and Children: Oral: 5 mg once every 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Adolescents: Oral: 25 mg once weekly (with pyrimethamine and dapsone) <b>or</b> 10 mg once daily (with pyrimethamine and atovaquone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Hematopoietic stem cell transplantation recipients:</p>
<p style="text-indent:-2em;margin-left:12em;">Children: Oral: 5 mg every 3 days; initiate after engraftment and administer as long as the patient remains on immunosuppressive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:12em;">Adolescents: Oral: 10 to 25 mg once daily; initiate after engraftment and administer as long as the patient remains on immunosuppressive therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19747629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19747629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Secondary (suppressive therapy): HIV-exposed/-infected:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children: Oral: 5 mg once every 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Adolescents: Oral: 10 to 25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pneumocystis jirovecii</i> pneumonia (PCP): Prophylaxis (primary and secondary): Adolescents: Oral: 25 mg once weekly (in combination with pyrimethamine and dapsone) <b>or</b> 10 mg once daily (in combination with pyrimethamine and atovaquone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Cystoisosporiasis<i> (formerly isosporiasis)</i>, HIV-exposed/-infected:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment, acute infection:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 5 to 15 mg once daily in combination with pyrimethamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 10 to 25 mg once daily in combination with pyrimethamine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Prophylaxis, secondary: </i></p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children: Oral: 5 to 15 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: Oral: 5 to 10 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96d5a89-d679-42f9-988b-a2ffb750c4b6">Methanol toxicity; adjunctive cofactor therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methanol toxicity; adjunctive cofactor therapy:</b> Limited data available: Infants, Children, and Adolescents: IV: 1 mg/kg/dose (maximum dose: 50 mg/dose) over 30 to 60 minutes every 4 to 6 hours. Therapy should continue until methanol and formic acid have been completely eliminated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12216995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12216995'])">Ref</a></span>).<b> Note:</b> Administration during methanol toxicity is especially important in patients who abuse ethanol as these patients may have chronic folate deficiency.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51117821"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51117822"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F187366"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9548" href="/d/html/9548.html" rel="external">see "Leucovorin: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Because oral absorption is saturable at doses &gt;25 mg, administering single oral doses &gt;25 mg is not recommended (convert to parenteral therapy). Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; when administering glucarpidase concomitantly with leucovorin calcium, administer leucovorin calcium ≥2 hours before or 2 hours after the glucarpidase dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29079637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29079637'])">Ref</a></span>). Do not administer leucovorin intrathecally; the use of intrathecal leucovorin is not advised (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8689347','lexi-content-ref-18570175']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8689347','lexi-content-ref-18570175'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b0a6d83-a7ac-4bd2-8948-9f49f264da2d">Acute lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphocytic leukemia (off-label use): </b>
<i>Hyper-CVAD alternating with high-dose methotrexate/cytarabine regimen: </i>
<b>IV:</b> 50 mg administered 12 hours after methotrexate completion, followed by 15 mg every 6 hours for 8 doses or until methotrexate level is &lt;0.1 micromolar (adjust dose based on methotrexate level as needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14551133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14551133'])">Ref</a></span>) <b>or </b>15 mg administered 12 hours after methotrexate completion, followed by 15 mg every 6 hours for 8 total doses or until methotrexate level is &lt;0.1 micromolar (adjust dose based on methotrexate level as needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15481055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15481055'])">Ref</a></span>). Therapy consists of alternating cycles of hyper-CVAD (cyclophosphamide, mesna, vincristine, doxorubicin, and dexamethasone) and high-dose methotrexate/cytarabine; refer to protocol for details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e025cb8a-09ac-4831-956d-eb46ce12c363">Biliary tract cancer, metastatic, progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Biliary tract cancer, metastatic, progressive (off-label use): IV: </b>400 mg/m<sup>2</sup> over 30 minutes once every 2 weeks (in combination with fluorouracil and irinotecan [liposomal]); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34656226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34656226'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9995c601-ff96-4efd-b9f3-99053a5ead64">Bladder cancer, neoadjuvant treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bladder cancer, neoadjuvant treatment (off-label use):</b>
<b>IV, Oral:</b> 15 mg every 6 hours for 4 doses on days 2 and 9, starting 24 hours after each methotrexate dose (in combination with methotrexate, vinblastine, and cisplatin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21502557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21502557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1bd2454-dab1-485c-8831-642cfd26eb29">Colorectal cancer, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, advanced: IV:</b> 200 mg/m<sup>2</sup>/day over ≥3 minutes for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks (in combination with fluorouracil) <b>or</b> 20 mg/m<sup>2</sup>/day for 5 days every 4 weeks for 2 cycles, then every 4 to 5 weeks (in combination with fluorouracil).<b> Note:</b> Multiple leucovorin-containing regimens are available for the treatment of colorectal cancer; may be in combination with other agents (eg, monoclonal antibodies). Refer to appropriate literature/guidelines for additional details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Roswell Park regimen (off-label dosing):</i>
<b>IV:</b> 500 mg/m<sup>2</sup> over 2 hours on days 1, 8, 15, 22, 29, and 36 (in combination with fluorouracil, administered 1 hour after the start of leucovorin) every 8 weeks for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16314627']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16314627'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX6 and mFOLFOX6 regimen (off-label dosing):</i>
<b>IV:</b> 400 mg/m<sup>2</sup> over 2 hours on day 1 <b>or </b>350 mg (flat dose) over 2 hours on day 1 (in combination with fluorouracil and oxaliplatin) every 2 weeks until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12177775','lexi-content-ref-10658524']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12177775','lexi-content-ref-10658524'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFOX7 regimen (off-label dosing):</i>
<b>IV: </b>200 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24608198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24608198'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRI regimen (off-label dosing):</i>
<b>IV:</b> 400 mg/m<sup>2</sup> over 2 hours on day 1 every 2 weeks (in combination with fluorouracil and irinotecan) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10658525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10658525'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOXIRI regimens:</i>
<b>IV: </b>200 mg/m<sup>2</sup> over 2 hours on day 1 every 14 days (in combination with fluorouracil, oxaliplatin, and irinotecan) until disease progression or unacceptable toxicity up to a maximum of 12 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17470860']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17470860'])">Ref</a></span>). Refer to protocol for further information.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9838f87f-41c7-4239-92f6-22c6626f72b4">Dermatomyositis/polymyositis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis/polymyositis (off-label use):</b>
<b>Oral:</b> 5 mg once per week (administered 8 to 12 hours after the methotrexate dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12895397','lexi-content-ref-Miller.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12895397','lexi-content-ref-Miller.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2897037a-475b-4a01-a1da-f6b2b0b16e38">Esophageal cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal cancer, advanced or metastatic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRI regimen:</i>
<b>IV: </b>400 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and irinotecan) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25287828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25287828'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLO regimen:</i>
<b>IV: </b>200 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18349393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18349393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOT regimen (locally advanced, resectable gastroesophageal junction adenocarcinoma):</i>
<b>IV:</b>
<b></b>200 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, oxaliplatin, and docetaxel) for 4 preoperative cycles and 4 postoperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30982686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30982686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX/nivolumab: </i>
<b>IV: </b>400 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, oxaliplatin, and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX4 regimen (chemoradiotherapy for locally advanced, recurrent, or metastatic disease): </i>
<b>IV: </b>200 mg/m<sup>2</sup> over 2 hours on day 1 every 2 weeks, in combination with fluorouracil and oxaliplatin and radiation for 3 cycles, then without radiation for 3 more cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20940718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20940718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFOX6 (metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction): </i>
<b>IV: </b>400 mg/m<sup>2</sup> over 2 hours on day 1 every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27382098']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27382098'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c29ec35b-1807-443e-8dde-8a015329e49e">Folic acid antagonist overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Folic acid antagonist (eg, trimethoprim, pyrimethamine) overdose:</b>
<b>Oral:</b> 5 to 15 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2133d38d-e6b0-4cbc-b6e4-19d85832c93e">Gastric cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastric cancer, advanced or metastatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRI regimen:</i>
<b>IV:</b> 400 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and irinotecan) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25287828']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25287828'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLO regimen:</i>
<b>IV: </b>200 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18349393']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18349393'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FLOT regimen: </i>
<b>IV: </b>200 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, oxaliplatin, and docetaxel) for 4 preoperative cycles and 4 postoperative cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30982686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30982686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFOX/nivolumab: </i>
<b>IV: </b>400 mg/m<sup>2</sup> on day 1 every 2 weeks (in combination with fluorouracil, oxaliplatin, and nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34102137']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34102137'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mDCF regimen (advanced gastric adenocarcinoma):</i>
<b>IV: </b>400 mg/m<sup>2</sup> over 30 minutes on day 1 every 2 weeks (in combination with docetaxel, fluorouracil, and cisplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26438119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26438119'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bd37b45c-f0bf-42b1-93a9-91edf9f9dd3e">Gestational trophoblastic neoplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic neoplasia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Low-risk disease:</b>
<i>8-day regimen:</i>
<b>Oral:</b> 30 mg every 48 hours (on days 2, 4, 6, and 8) for 4 doses (30 hours after each methotrexate dose), repeat cycle every 14 days until hCG level is normal, followed by 2 to 3 more cycles as consolidation therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33384141']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33384141'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>High-risk metastatic disease:</b>
<b>Note:</b> The oral route would be preferred over IM in patients with thrombocytopenia.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>EMA-CO regimen: </i>
<b>Oral, IM: </b>15 mg every 12 hours for 4 doses, beginning 24 hours after the start of methotrexate (in combination with etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine); patients with brain metastases received a higher methotrexate dose and, therefore, the leucovorin calcium dose was increased to 30 mg every 12 hours for 6 doses, beginning 32 hours after the start of methotrexate. Continue for ≥2 treatment cycles after a normal human chorionic gonadotropin (hCG) level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14675675','lexi-content-ref-17086804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14675675','lexi-content-ref-17086804'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>EMA-EP regimen:</i>
<b>Oral, IM: </b>15 mg every 12 hours for 4 doses beginning on day 2 (in combination with etoposide, methotrexate, dactinomycin, and cisplatin); patients with brain metastases received a higher methotrexate dose and, therefore, an increased leucovorin calcium dose of 30 mg every 12 hours. Continue for 2 to 4 treatment cycles after a normal hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15086738']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15086738'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>EP-EMA regimen:</i>
<b>Oral, IM: </b>15 mg every 12 hours for 4 doses, beginning 24 hours after the start of methotrexate (in combination with etoposide, cisplatin, methotrexate, and dactinomycin); if mucositis develops, may double the dose and duration of leucovorin calcium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10673528']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10673528'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="59e38d44-f7f8-46cb-81e2-809dd0575e0c">Graft-versus-host disease, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, acute (prophylaxis) (off-label use):</b>
<b>IV, Oral:</b> 15 mg every 6 hours for 3 doses on day 2, then 15 mg every 6 hours for 4 doses on days 4, 7, and 12 (in combination with methotrexate and cyclosporine); initiate leucovorin 24 hours after each methotrexate dose (methotrexate is administered on days 1, 3, 6, and 11; may omit day 11 methotrexate for ≥ grade 2 toxicity) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23892326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23892326'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="eb007dc6-895a-4a2a-b099-9ecdac79ad9e">Granulomatosis with polyangiitis and microscopic polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Granulomatosis with polyangiitis and microscopic polyangiitis (maintenance therapy after remission induction) (off-label use):</b>
<b>Oral:</b> 5 to 10 mg once weekly administered 24 hours after methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12727579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12727579'])">Ref</a></span>) <b>or</b> 25 mg once weekly administered 48 hours after methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19109574']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19109574'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="551405cb-d482-4c00-9af3-e01f6e24ce2c">Hepatobiliary cancers, advanced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatobiliary cancers, advanced (off-label use):</b>
<b>IV:</b> 25 mg/m<sup>2</sup> immediately prior to fluorouracil infusion on days 1, 8, and 15 every 4 weeks (in combination with gemcitabine and fluorouracil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15558814']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15558814'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f71016a0-564d-45cd-baea-d684015a19df">Megaloblastic anemia, folate-deficient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Megaloblastic anemia, folate-deficient:</b>
<b>IM, IV:</b> ≤1 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b1d502c5-fbb8-42a4-9633-67f5e475a24f">Methanol toxicity, adjunctive cofactor therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methanol toxicity, adjunctive cofactor therapy (off-label use):</b>
<b>IV:</b> 1 mg/kg (maximum dose: 50 mg) over 30 to 60 minutes every 4 to 6 hours. Therapy should continue until methanol and formic acid have been completely eliminated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12216995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12216995'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a51599fe-4a98-41ab-8bc8-139db6d120b8">Methotrexate-rescue, high-dose methotrexate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methotrexate-rescue, high-dose methotrexate:</b> Initial: <b>Oral, IM, IV:</b> 15 mg (~10 mg/m<sup>2</sup>); start 24 hours after beginning methotrexate infusion; continue every 6 hours for 10 doses, until methotrexate level is &lt;0.05 micromolar. Monitor hydration and electrolyte status, as well as urine alkalinization. Adjust dose per institutional protocol or as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Normal methotrexate elimination (serum methotrexate level ~10 micromolar at 24 hours after administration, 1 micromolar at 48 hours, and &lt;0.2 micromolar at 72 hours):</i>
<b>Oral, IM, IV:</b> 15 mg every 6 hours for 60 hours (10 doses) beginning 24 hours after the start of methotrexate infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Delayed late methotrexate elimination (serum methotrexate level remaining &gt;0.2 micromolar at 72 hours and &gt;0.05 micromolar at 96 hours after administration):</i> Continue leucovorin calcium 15 mg (<b>oral, IM, or IV</b>) every 6 hours until methotrexate level is &lt;0.05 micromolar.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Delayed early methotrexate elimination and/or acute renal injury (serum methotrexate level ≥50 micromolar at 24 hours, or ≥5 micromolar at 48 hours, or a doubling of serum creatinine level at 24 hours after methotrexate administration):</i>
<b>IV:</b> 150 mg every 3 hours until methotrexate level is &lt;1 micromolar, then 15 mg every 3 hours until methotrexate level is &lt;0.05 micromolar.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0573b33c-e721-4778-b9fb-47e7887d3ec0">Methotrexate overdose, inadvertent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methotrexate overdose, inadvertent: Note:</b> Begin as soon as possible after overdose. <b>Oral, IM, IV:</b> 10 mg/m<sup>2</sup> every 6 hours until the methotrexate level is &lt;0.01 micromolar. If serum creatinine is increased &gt;50% above baseline 24 hours after methotrexate administration, if 24 hour methotrexate level is &gt;5 micromolar, or if 48 hour methotrexate level is &gt;0.9 micromolar, increase leucovorin dose to 100 mg/m<sup>2</sup>
<b>IV</b> every 3 hours until the methotrexate level is &lt;0.01 micromolar.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3cae8ee-43cc-4688-b53d-84b379527273">Methotrexate overexposure, high-dose methotrexate</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Methotrexate overexposure, high-dose methotrexate:</b> Leucovorin nomogram dosing for high-dose methotrexate overexposure (off-label dosing; generalized dosing derived from reference nomogram figures, refer to each reference (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-342086','lexi-content-ref-Bleyer.1','lexi-content-ref-16794248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-342086','lexi-content-ref-Bleyer.1','lexi-content-ref-16794248'])">Ref</a></span>) or institution-specific nomogram for details):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>At 24 hours:</b></p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥100 micromolar at ~24 hours, leucovorin calcium is initially dosed at 1,000 mg/m<sup>2</sup>
<b>IV</b> every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥10 to &lt;100 micromolar at 24 hours, leucovorin calcium is initially dosed at 100 mg/m<sup>2</sup>
<b>IV</b> every 3 or 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ~1 to 10 micromolar at 24 hours, leucovorin calcium is initially dosed at 10 mg/m<sup>2</sup>
<b>IV or orally</b> every 3 or 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>At 48 hours:</b></p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥100 micromolar at 48 hours, leucovorin calcium is dosed at 1,000 mg/m<sup>2</sup>
<b>IV</b> every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥10 to &lt;100 micromolar at 48 hours, leucovorin calcium is dosed at 100 mg/m<sup>2</sup>
<b>IV</b> every 3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ~1 to 10 micromolar at 48 hours, leucovorin calcium is dosed at 100 mg/m<sup>2</sup>
<b> IV</b> every 6 hours <b>or </b>10 mg/m<sup>2</sup>
<b>IV or orally</b> to 100 mg/m<sup>2</sup>
<b>IV</b> every 3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>At 72 hours:</b></p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ≥10 micromolar at 72 hours, leucovorin calcium is dosed at 100 to 1,000 mg/m<sup>2</sup>
<b>IV</b> every 3 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ~1 to 10 micromolar at 72 hours, leucovorin calcium is dosed at 10 mg/m<sup>2</sup>
<b>IV or</b>
<b>orally</b> to 100 mg/m<sup>2</sup>
<b>IV</b> every 3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">For methotrexate levels of ~0.1 to 1 micromolar at 72 hours, leucovorin calcium is dosed at 10 mg/m<sup>2</sup>
<b>IV</b>
<b>or orally</b> every 3 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">If serum creatinine is increased &gt;50% above baseline, increase the standard leucovorin calcium dose to 100 mg/m<sup>2</sup>
<b>IV</b> every 3 hours, then adjust according to methotrexate levels above.</p>
<p style="text-indent:-2em;margin-left:4em;">Follow methotrexate levels daily, leucovorin calcium may be discontinued when methotrexate level is &lt;0.1 micromolar.</p>
<p style="text-indent:-2em;margin-left:4em;">Some regimens use the following equation when calculating the leucovorin calcium dose (if the methotrexate plasma concentration is &gt;5 micromolar) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29079637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29079637'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Plasma methotrexate concentration (micromolar) × body weight (kg)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="92aa864a-fcee-48a6-987c-ed11403c7b21">Non-Hodgkin lymphoma, Burkitt</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma, Burkitt (off-label use):</b></p>
<p style="text-indent:-4em;margin-left:6em;">
<i>CODOX-M/IVAC regimen:</i>
<b>IV, Oral:</b> 15 mg/m<sup>2</sup>
<b>IV</b> every 3 hours for 5 doses beginning at hour 36 after the start of methotrexate, then 15 mg/m<sup>2</sup>
<b>IV</b> every 6 hours until methotrexate level is &lt;0.05 micromolar. In addition, leucovorin calcium 15 mg (flat dose) <b>orally</b> is administered 24 hours after intrathecal methotrexate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18612102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18612102'])">Ref</a></span>). CODOX-M cycle (cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate with leucovorin calcium rescue, intrathecal cytarabine, and intrathecal methotrexate) alternates with IVAC cycle (etoposide, ifosfamide, mesna, cytarabine, and intrathecal methotrexate (with leucovorin calcium rescue); refer to protocol for details.</p>
<p style="text-indent:-4em;margin-left:6em;">
<i>Hyper-CVAD alternating with high-dose methotrexate/cytarabine regimen: </i>
<b>IV, Oral: </b>50 mg IV administered 12 hours after methotrexate completion, followed by 15 mg IV every 6 hours for 8 doses or until methotrexate level is &lt;0.1 micromolar (adjust dose based on methotrexate level as needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413'])">Ref</a></span>) <b>or</b> 50 mg IV administered 24 hours after the end of methotrexate infusion, followed by 15 mg orally every 6 hours for 8 doses (adjust dose based on methotrexate level as needed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9850025']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9850025'])">Ref</a></span>). Therapy consists of alternating cycles of hyper-CVAD (cyclophosphamide, mesna, vincristine, doxorubicin, and dexamethasone) and high-dose methotrexate/cytarabine; refer to protocol for details.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49e41d16-77ea-49f7-a32a-865bf8bfa071">Nonleukemic meningeal cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonleukemic meningeal cancer (off-label use):</b>
<b>Oral:</b> 10 mg every 6 hours for 8 doses, beginning 24 hours after each intrathecal methotrexate dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10589750']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10589750'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a2ef5d06-eb08-4064-9765-eeb1fa388d2e">Pancreatic cancer, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, advanced or metastatic (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRINOX regimen:</i>
<b>IV: </b>400 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil, oxaliplatin, and irinotecan) for ≥6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21561347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21561347'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>OFF regimen (second-line therapy):</i>
<b>IV: </b>200 mg/m<sup>2</sup> on days 1, 8, 15, and 22 every 6 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24982456','lexi-content-ref-21565490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24982456','lexi-content-ref-21565490'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3a39e464-8bb6-4795-a1b3-a3b1646f0ac0">Pancreatic cancer, potentially curable, adjuvant therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pancreatic cancer, potentially curable, adjuvant therapy (off-label use):</b>
<b>Note:</b> American Society of Clinical Oncology (ASCO) guidelines recommend 6 months of adjuvant therapy if recovery is complete; if preoperative chemotherapy therapy was received, a total of 6 months of adjuvant therapy (including the preoperative regimen) is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRINOX regimen: </i>
<b>IV:</b> 400 mg/m<sup>2</sup> over 2 hours once every 2 weeks (in combination with fluorouracil, irinotecan, and oxaliplatin; modified FOLFIRINOX regimen) for 24 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575490'])">Ref</a></span>). According to ASCO guidelines, mFOLFIRINOX is the preferred first-line adjuvant regimen for potentially curable disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180816']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180816'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75ddb519-523e-44da-bdc9-aed5a9664ca9">Prevention of pyrimethamine hematologic toxicity in patients with HIV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prevention of pyrimethamine hematologic toxicity in patients with HIV (off-label use)</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-HHS.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-HHS.3'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Cystoisosporiasis (formerly Isosporiasis):</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment: <b>Oral:</b> 10 to 25 mg once daily (in combination with pyrimethamine).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic maintenance (secondary prophylaxis): <b>Oral: </b>5 to 10 mg once daily (in combination with pyrimethamine).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pneumocystis </i>pneumonia: Prophylaxis (primary and secondary): <b>Oral: </b>25 mg once weekly (in combination with pyrimethamine and dapsone) <b>or</b> 10 mg once daily (in combination with pyrimethamine and atovaquone).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Toxoplasma gondii</i> encephalitis:</p>
<p style="text-indent:-2em;margin-left:6em;">Primary prophylaxis: <b>Oral: </b>25 mg once weekly (in combination with pyrimethamine and dapsone) <b>or</b> 10 mg once daily (in combination with pyrimethamine and atovaquone).</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment: <b>Oral: </b>10 to 25 mg once daily as part of an appropriate combination regimen. <b>Note:</b> May increase leucovorin to 50 mg once or twice daily in cases of pyrimethamine toxicity (rash, nausea, bone marrow suppression).</p>
<p style="text-indent:-2em;margin-left:6em;">Chronic maintenance (secondary prophylaxis): <b>Oral: </b>10 to 25 mg once daily (in combination with pyrimethamine with either sulfadiazine or clindamycin) <b>or</b> 10 mg once daily (in combination with pyrimethamine and atovaquone).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="742c866d-624d-41cf-a1cb-742554aedc03">Primary CNS lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary CNS lymphoma (off-label use):</b>
<b>IV, Oral:</b> 20 to 25 mg every 6 hours beginning 24 hours after methotrexate infusion (in combination with rituximab, methotrexate, vincristine, and procarbazine, followed by radiotherapy, cytarabine, and intra-Ommaya methotrexate), continue for ≥72 hours or until methotrexate level is &lt;0.1 micromolar; may increase dose to 40 mg every 4 hours for elevated methotrexate levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17947720']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17947720'])">Ref</a></span>) <b>or</b> 100 mg/m<sup>2</sup>
<b>IV</b> every 6 hours starting 24 hours after methotrexate infusion, continue until methotrexate level is &lt;0.05 micromolar (in combination with methotrexate, temozolomide, and rituximab, followed by high-dose consolidation therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12637469','lexi-content-ref-23569323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12637469','lexi-content-ref-23569323'])">Ref</a></span>) <b>or</b> 25 mg <b>IV</b> every 6 hours starting 24 hours after methotrexate, continue until appropriate methotrexate level is reached (in combination with methotrexate, temozolomide, and rituximab, followed by whole brain radiotherapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27022122']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27022122'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dee8164d-cd60-4a64-9145-01decfe018bd">Small bowel adenocarcinoma, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small bowel adenocarcinoma, advanced or metastatic (off-label use): Note: </b>Ampullary adenocarcinomas were excluded from these studies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22481063','lexi-content-ref-20223786','lexi-content-ref-21425142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22481063','lexi-content-ref-20223786','lexi-content-ref-21425142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FOLFIRI regimen (following progression on a platinum-based regimen): </i>
<b>IV: </b>400 mg/m<sup>2</sup> over 2 hours on day 1 every 2 weeks (in combination with fluorouracil and irinotecan) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21425142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21425142'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>mFOLFOX or FOLFOX regimen:</i>
<b>IV:</b> 400 mg/m<sup>2</sup> over 2 hours on day 1 every 2 weeks (in combination with fluorouracil and oxaliplatin) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22481063','lexi-content-ref-20223786']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22481063','lexi-content-ref-20223786'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c89560b3-38b8-4ff8-85f5-a7472ee7f941">Tubal ectopic pregnancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tubal ectopic pregnancy (off-label use) </b>(in combination with a multidose methotrexate regimen): <b>IM:</b> Methotrexate on days 1, 3, 5, and 7 alternating with leucovorin calcium 0.1 mg/kg on days 2, 4, 6, and 8. Measure serum hCG on each day of methotrexate administration. If serum hCG decreases by &gt;15% from previous measurement, discontinue methotrexate and leucovorin (total treatment may be between 1 and 4 doses each). If serum hCG decreases by &lt;15% from previous measurement, administer methotrexate (maximum 4 doses) and then leucovorin calcium the next day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470343','lexi-content-ref-23849842','lexi-content-ref-2444463','lexi-content-ref-2784113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470343','lexi-content-ref-23849842','lexi-content-ref-2444463','lexi-content-ref-2784113'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990699"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50988026"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F187337"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in combination with 5-fluorouracil.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (≤13%), lethargy (≤13%), malaise (≤13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (42% to 43%), dermatitis (21% to 25%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Stomatitis (75% to 84%; grades ≥3: 27% to 29%), nausea (74% to 80%), diarrhea (66% to 67%), vomiting (44% to 46%), anorexia (14% to 22%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Drug toxicity</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (3% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Gastrointestinal: Gastrointestinal toxicity</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Anaphylactic shock, anaphylaxis, hypersensitivity reaction, nonimmune anaphylaxis, seizure, syncope, urticaria</p></div>
<div class="block coi drugH1Div" id="F187350"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Pernicious anemia and other megaloblastic anemias secondary to vitamin B<sub>12</sub>-deficiency</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Hypersensitivity to leucovorin or any component of the formulation; intrathecal administration</p></div>
<div class="block war drugH1Div" id="F5524355"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity, including allergic reactions, anaphylactoid reactions, and urticaria have been reported with leucovorin. Because leucovorin is typically administered in combination with other chemotherapy agents, it may be difficult to determine the causative agent for hypersensitivity reactions. In a series of 44 patients with hypersensitivity to leucovorin-containing regimens, hypersensitivity/infusion reaction to leucovorin was confirmed in 5 patients; reactions also occurred with subsequent rechallenge with LEVOleucovorin (Ureña-Tavera 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: Seizures or syncope have been reported (rarely) in patients with cancer receiving leucovorin, usually in association with fluoropyrimidine administration, and most commonly in patients with CNS metastases or other predisposing factors; a causal relationship has not been established.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anemias: Leucovorin is inappropriate treatment for pernicious anemia and other megaloblastic anemias secondary to a lack of vitamin B<sub>12</sub>; a hematologic remission may occur while neurologic manifestations progress.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Leucovorin is excreted renally; the risk for toxicities may be increased in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fluorouracil: Leucovorin may increase the toxicity of 5-fluorouracil; deaths from severe enterocolitis, diarrhea, and dehydration have been reported (in elderly patients); granulocytopenia and fever have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfamethoxazole-trimethoprim: The combination of leucovorin and sulfamethoxazole-trimethoprim for the acute treatment of <i>Pneumocystis jirovecii </i>pneumonia in patients with HIV infection has been reported to cause increased rates of treatment failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Administration route: Parenteral administration may be preferred to oral if vomiting or malabsorption is likely. Because oral absorption is saturable at doses &gt;25 mg, administering oral doses &gt;25 mg is not recommended (convert to parenteral therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: When doses &gt;10 mg/m<sup>2</sup> are required using the powder for injection, reconstitute using sterile water for injection, not a solution containing benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Injection: Due to calcium content, do not administer IV solutions at a rate &gt;160 mg/minute. Not intended for intrathecal use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings and precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Folic acid antagonist overdose: When used for the treatment of accidental folic acid antagonist overdose, administer as soon as possible.</p>
<p style="text-indent:-2em;margin-left:4em;">• Methanol toxicity: Leucovorin is the reduced form of folic acid; leucovorin is rapidly converted to tetrahydrofolic acid derivatives, which are the storage forms of folate in the body. Because leucovorin does not require metabolic reduction, it is the preferred form of folate in the treatment of methanol toxicity. Administration during methanol toxicity is especially important in patients with chronic alcohol use disorder as these patients may have chronic folate deficiency. Clinicians should note that leucovorin is an adjunctive therapy and should never be used as the sole intervention in the management of methanol toxicity (AACT [Barceloux 2002]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Methotrexate overdose: When used for the treatment of a methotrexate overdose, administer IV leucovorin as soon as possible. Monitoring of the serum methotrexate concentration is essential to determine the optimal dose/duration of leucovorin; however, do not wait for the results of a methotrexate level before initiating leucovorin. It is important to adjust the leucovorin dose once a methotrexate level is known. The dose may need to be increased or administration prolonged in situations in which methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration). <b>Never administer leucovorin intrathecally.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Methotrexate rescue therapy: Methotrexate serum concentrations should be monitored to determine dose and duration of leucovorin therapy. Dose may need to be increased or administration prolonged in situations where methotrexate excretion may be delayed (eg, ascites, pleural effusion, renal insufficiency, inadequate hydration). <b>Never administer leucovorin intrathecally. </b></p></div>
<div class="block foc drugH1Div" id="F187344"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/10 mL (10 mL); 500 mg/50 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 100 mg (1 ea); 200 mg (1 ea); 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg (1 ea); 100 mg (1 ea); 200 mg (1 ea); 350 mg (1 ea); 500 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 15 mg, 25 mg</p></div>
<div class="block geq drugH1Div" id="F187331"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F2524636"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Leucovorin Calcium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/10 mL (per mL): $2.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/50 mL (per mL): $2.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Leucovorin Calcium Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $12.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $19.20 - $24.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $12.00 - $48.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">350 mg (per each): $31.20 - $84.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $103.43 - $120.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Leucovorin Calcium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1.68 - $2.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $8.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 mg (per each): $11.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $11.18 - $24.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867342"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/5 mL (5 mL); 200 mg/20 mL (20 mL); 1000 mg/100 mL (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/mL (5 mL, 30 mL, 50 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 15 mg</p></div>
<div class="block exp drugH1Div" id="F12807804"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">A 5 mg/mL oral suspension may be prepared with tablets, Cologel, and a 2:1 mixture of simple syrup and wild cherry syrup. Crush twenty-four 25 mg tablets in a glass mortar and reduce to a fine powder; transfer powder to amber bottle. Add 30 mL Cologel and shake mixture thoroughly. Add a quantity of syrup mixture sufficient to make 120 mL. Label “shake well” and “refrigerate”. Stable for 28 days refrigerated.</p>
<div class="reference">Lam MS. Extemporaneous Compounding of Oral Liquid Dosage Formulations and Alternative Drug Delivery Methods for Anticancer Drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192.<span class="pubmed-id">21275495</span></div>
</div>
<div class="block admp drugH1Div" id="F52613136"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Do not administer orally in the presence of nausea or vomiting. Because oral absorption is saturable at doses above 25 mg, administering oral doses &gt;25 mg is not recommended (convert to parenteral therapy).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Due to calcium content, do not administer IV solutions at a rate &gt;160 mg/minute; <b>not intended for intrathecal use</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Refer to individual protocols. Should be administered IM, IV push, or IV infusion (15 minutes to 2 hours). Leucovorin should not be administered concurrently with methotrexate. It is commonly initiated 24 hours after the start of methotrexate. Toxicity to normal tissues may be irreversible if leucovorin is not initiated by ~40 hours after the start of methotrexate.</p>
<p style="text-indent:-2em;margin-left:4em;">As a rescue after folate antagonists: Administer by IV bolus, IM, or orally.</p>
<p style="text-indent:-2em;margin-left:4em;">Combination therapy with fluorouracil: Fluorouracil is usually given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by IV bolus injection or short (10 to 120 minutes) IV infusion. Other administration schedules have been used; refer to individual protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">For the treatment of methanol toxicity, infuse over 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12216995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12216995'])">Ref</a></span>)</p></div>
<div class="block adm drugH1Div" id="F187347"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Due to calcium content, do not administer IV solutions at a rate &gt;160 mg/minute; not intended for intrathecal use.</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to individual protocols. Should be administered IM, IV push, or IV infusion (15 minutes to 2 hours). Leucovorin should not be administered concurrently with methotrexate. It is commonly initiated 24 hours after the start of methotrexate. Leucovorin calcium is a substrate for glucarpidase and may compete with methotrexate for binding sites; when administering glucarpidase concomitantly with leucovorin calcium, administer leucovorin calcium at least 2 hours before or 2 hours after the glucarpidase dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29079637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29079637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">As a rescue after folate antagonists: Administer by IV bolus, IM, or orally.</p>
<p style="text-indent:-2em;margin-left:2em;">Do not administer orally in the presence of nausea or vomiting. Because oral absorption is saturable at doses &gt;25 mg, administering oral doses &gt;25 mg is not recommended (convert to parenteral therapy).</p>
<p style="text-indent:-2em;margin-left:2em;">Combination therapy with fluorouracil: Fluorouracil is usually given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by IV bolus injection or short (10 to 120 minutes) IV infusion. Other administration schedules have been used; refer to individual protocols.</p>
<p style="text-indent:-2em;margin-left:2em;">For the treatment of methanol toxicity, infuse over 30 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12216995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12216995'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F187359"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Powder for injection: Store intact vials and reconstituted solution at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light. Solutions reconstituted with bacteriostatic water for injection USP must be used within 7 days. Solutions reconstituted with SWFI must be used immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution for injection: Prior to dilution, store vials at 2°C to 8°C (36°F to 46°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablet: Store at 20°C to 25°C (68°F to 77°F). Protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 300 to 1,000 mg of leucovorin be stocked. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53567487"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Rescue agent to diminish the toxicity and counteract the effects of impaired methotrexate elimination or as an antidote for folic acid antagonist overdosage (FDA approved in pediatric patients [age not specified] and adults); has also been used in the treatment of folinic acid responsive seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Rescue agent after high-dose methotrexate treatment in osteosarcoma and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; treatment of megaloblastic anemias due to folic acid deficiency (when oral therapy is not feasible) (FDA approved in pediatric patients [age not specified] and adults); treatment of advanced colorectal cancer (palliative) in combination with fluorouracil (FDA approved in adults); has also been used as rescue agent after high-dose methotrexate treatment in treatment of other cancers; as adjunctive cofactor therapy in methanol toxicity, adjunctive treatment with sulfadiazine and pyrimethamine to prevent hematologic toxicity.</p></div>
<div class="block mst drugH1Div" id="F187410"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Leucovorin calcium may be confused with Leukeran, Leukine, LEVOleucovorin</p>
<p style="text-indent:-2em;margin-left:4em;">Folinic acid may be confused with folic acid</p>
<p style="text-indent:-2em;margin-left:4em;">Folinic acid is an error prone synonym and should not be used</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299583"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F187338"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Fluorouracil Products: Leucovorin Calcium-Levoleucovorin may enhance the adverse/toxic effect of Fluorouracil Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucarpidase: May decrease serum concentrations of the active metabolite(s) of Leucovorin Calcium-Levoleucovorin. Specifically, 6S-5-methyltetrahydrofolateconcentrations may be reduced. Glucarpidase may decrease the serum concentration of Leucovorin Calcium-Levoleucovorin. Management: Avoid leucovorin administration within 2 hours of glucarpidase dosing. Continue to administer the pre-glucarpidase leucovorin dose for at least the first 48 hours after glucarpidase administration, and dose based on methotrexate concentration thereafter.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: Leucovorin Calcium-Levoleucovorin may decrease the serum concentration of Primidone. Additionally, leucovorin/levoleucovorin may decrease concentrations of active metabolites of primidone (e.g., phenobarbital). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltitrexed: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Raltitrexed. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: Leucovorin Calcium-Levoleucovorin may diminish the therapeutic effect of Trimethoprim.  Management: Avoid concurrent use of leucovorin or levoleucovorin with trimethoprim (plus sulfamethoxazole) for <i>Pneumocystis jirovecii</i> pneumonia.  If trimethoprim is used for another indication, monitor closely for reduced efficacy.<i> Risk X: Avoid combination</i></p></div>
<div class="block dic drugH1Div" id="F5524286"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Solutions for injection contain calcium 0.004 mEq per leucovorin 1 mg</p></div>
<div class="block pri drugH1Div" id="F5524281"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Leucovorin is a biologically active form of folic acid. Adequate amounts of folic acid are recommended during pregnancy. Refer to Folic Acid monograph.</p></div>
<div class="block mopp drugH1Div" id="F53567475"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;">High-dose methotrexate therapy: CBC with differential; serum creatinine; plasma methotrexate concentrations. Leucovorin is continued until the plasma methotrexate concentration is &lt;0.1 micromolar (1 x 10<sup>-7</sup> molar) or &lt;0.05 micromolar (0.5 x 10<sup>-7</sup> molar) in situations of delayed methotrexate clearance. With 4- to 6-hour high-dose methotrexate infusions, plasma drug values in excess of 50 micromolar (5 x 10<sup>-5</sup> M) and 1 micromolar (10<sup>-6</sup> M) at 24 and 48 hours after starting the infusion, respectively, are often predictive of delayed methotrexate clearance. Monitor fluid and electrolyte status in patients with delayed methotrexate elimination (likely to experience renal toxicity).</p>
<p style="text-indent:0em;margin-top:2em;">When used with fluorouracil: CBC with differential, platelets, LFTs, electrolytes </p></div>
<div class="block pha drugH1Div" id="F187334"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Leucovorin calcium is a reduced form of folic acid, leucovorin supplies the necessary cofactor blocked by methotrexate. Leucovorin actively competes with methotrexate for transport sites, displaces methotrexate from intracellular binding sites, and restores active folate stores required for DNA/RNA synthesis. Leucovorin stabilizes the binding of 5-dUMP and thymidylate synthetase, enhancing the activity of fluorouracil. When administered with pyrimethamine for the treatment of opportunistic infections, leucovorin reduces the risk for hematologic toxicity (HHS [OI adult 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Methanol toxicity treatment: Formic acid (methanol’s toxic metabolite) is normally metabolized to carbon dioxide and water by 10-formyltetrahydrofolate dehydrogenase after being bound to tetrahydrofolate. Administering a source of tetrahydrofolate may aid the body in eliminating formic acid (AACT [Barceloux 2002]).</p></div>
<div class="block phk drugH1Div" id="F187349"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral, IM: Well absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Intestinal mucosa and hepatically to 5-methyl-tetrahydrofolate (5MTHF; active) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Saturable at oral doses &gt;25 mg; 25 mg (97%), 50 mg (75%), 100 mg (37%) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~4 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Oral: ~2 hours; IV: Total folates: 10 minutes; 5MTHF: ~1 hour; IM: Total folates: 52 minutes; 5MTHF: 2.8 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (primarily); feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F187352"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Calcium leucovorin | Calciumfolinat | Chemonate</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Asovorin | Elvefocal | Estroquin | Folinfabra | Leucocalcin | Leucovorina calcica teva | Leucovorina delta farma | Leucovorina filaxis | Leucovorina gp pharm | Leucovorina raffo | Leucovorina richet | Leucovorina servycal | Rontafor</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Calciumfolinat | Leucovorin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Calcium leucovorin | Leucovorin calcium</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Biofol | Folita</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Rescuvolin</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Calfolin | Folicorin | Folinac | Folinato de calcio | Leucovorina calcica | Levorin | Nyrin | Prevax | Rescuvolin | Tecnovorin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Leucovorina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai jie kang | Ai ru xi | Antrex | Ao luo ya | Bo sheng | Fu li neng | Fu neng | Gai er qing | Leucovorin calcium | Ou li | Rescuvolin | Shi ming | Tong ao</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Alonat | Dalisol | Folical | Folinato de calcio | Leucovorin calcium | Leucovorina | Lucal | Rescuvolin | Tecnovorin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Leucovorin calcium</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Calciumfolinat | Calciumfolinat gry | Lederfolat | Leucovorin | Rescuvolin | Zytofolin</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Calciumfolinat mayne</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Leucovorina Calcico</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Leucovorina | Tecnovorin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Antrex | Leucovorin | Neovorin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Nyrin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cromatonbic folinico | Folidan | Folinato calcico G.E.S | Folinato calcico Normon | Lederfolin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Antrex | Leucovorin | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Folinate de calcium aguettant | Folinate de calcium altan | Folinate de calcium dakota pharm | Folinate de calcium zentiva | Lederfoline | Perfolate</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Calc leucovorn | Calcium folint | Calcium leucovorn | Folic acid roche | Lederfolin | Refolinon</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Calcifolin | Calcium leucovorin | Claro | Fedolen | Folical | Folinacid | Folinato | Foxolin | Leucovorin | Reotan | Rescuvolin | Vivalcid</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Leucovorin calcium | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Lederfoline | Leucovorin ca | Leucovorin teva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Erbanfol | Leucovorin calcium | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Folinic acid | Leucovorin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adcov | Biovorin | Fastovorin | Leucorin | Leucovorin | Leucovorin calcium | Leutero | Neovorin | Nyrin | Recovorin | Unifolin | Zovorin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Calcio Folinato | Calcium Folinato | Calfolex | Calinat | Citofolin | Divifolin | Ecofol | Folaren | Foliben | Folidar | Folinvit | Foliplus | Lederfolin | Resfolin | Sanifolin | Sulton | Tonofolin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin calcium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Calcium folinate nk | Folinate dsep | Folinate jg | Folinate ohara | Folinate sawai | Folinate towa | Uzel</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Ferbon | Leucovorin | Nyrin | Rescuvolin | Robin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin calcium</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Antrex | Calcifolin | Calciumfolinat | Lederfolat | Leucovorin calcium</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Ledervorin | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Antrex | Lederfolat | Leucovorin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acido folinico | Dalisol | Ifavor | Leucovorin | Medsavorina</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Folina | Leucovorin | Leucovorin calcium | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Calciumfolinaat Ebewe | Leucovorine | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Calciumfolinate teva | Kalsiumfolinat | Leucovorin | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Leucovorin calcium</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Etamolin | Folinato calcico | Folinato de calcio | Leucovorina | Tecnovorin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Rescuvolin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Antrex | Biovorin | Calcium folinate actavis | Calcium folinate hospira | Lederfolat | Leucovorin | Leucovorin ca | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Leucovorin calcium</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Folinato Calcico Teva | Lederfoline</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Estroquin | Leucocalcin | Leucovorin libra | Leucovorina calcica fapasa | Leucovorina fapasa | Leucovorina fusa | Novizet | Rontafor</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Folcasin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Calcium folinate vial | Dalisol | Leikovorin lahema | Leucovorin | Leucovorin Lachema | Leucovorin lens | Leucovorine lans</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Calcium leucovorin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Calciumfolinate teva | Leucovorin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Leucovorin calcium | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Leucovorin ca</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Calciumfolinat ebewe | Folina | Leucovorin calcium | Leucovorin dabur | Leukovorin | Nyrin | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Folinate calcium | Folinate de calcium aguettant | Lederfoline | Protektor</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Antrex | Calciumfolinat ebewe | Folca | Leucovorin teva | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Antrex | Bloodlet | Cafonia | Calciumfolinat | Calife | Folina | Leucovorin | Leucovorin calcium | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Leucovorin | Leucovorin amaxa | Leucovorin calcium | Leucovorin lens</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Folinato de calcio | Leucovorin | Leucovorina | Rontafor</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Leuconolver</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Abic leucovorin | Folinic acid | Leucovorin | Leucovorin faulding | Rescuvolin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Unifolin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Rescuvolin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25274592">
<a name="25274592"></a>Al-Baradie RS, Chaudhary MW. Diagnosis and management of cerebral folate deficiency. A form of folinic acid-responsive seizures. <i>Neurosciences (Riyadh)</i>. 2014;19(4):312‐316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/25274592/pubmed" id="25274592" target="_blank">25274592</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18349393">
<a name="18349393"></a>Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. <i>J Clin Oncol.</i> 2008;26(9):1435-1442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/18349393/pubmed" id="18349393" target="_blank">18349393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30982686">
<a name="30982686"></a>Al-Batran SE, Homann N, Pauligk C, et al; FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. <i>Lancet</i>. 2019;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/30982686/pubmed" id="30982686" target="_blank">30982686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15558814">
<a name="15558814"></a>Alberts SR, Al-Khatib H, Mahoney MR, et al. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. <i>Cancer.</i> 2005;103(1):111-118. doi:10.1002/cncr.20753<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/15558814/pubmed" id="15558814" target="_blank">15558814</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470343">
<a name="29470343"></a>American College of Obstetricians and Gynecologists ACOG Practice Bulletin No. 193: tubal ectopic pregnancy. <i>Obstet Gynecol</i>. 2018;131(3):e91-e103. doi: 10.1097/AOG.0000000000002560.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/29470343/pubmed" id="29470343" target="_blank">29470343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10658525">
<a name="10658525"></a>André T, Louvet C, Maindrault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. <i>Eur J Cancer</i>. 1999;35(9):1343-1347. doi: 10.1016/s0959-8049(99)00150-1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/10658525/pubmed" id="10658525" target="_blank">10658525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27247216">
<a name="27247216"></a>Balaban EP, Mangu PB, Khorana AA, et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline.<i> J Clin Oncol</i>. 2016;34(22):2654-2668. doi: 10.1200/JCO.2016.67.5561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/27247216/pubmed" id="27247216" target="_blank">27247216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12216995">
<a name="12216995"></a>Barceloux DG, Bond GR, Krenzelok EP, et al. American Academy of Clinical Toxicology practice guidelines on the treatment of methanol poisoning. <i>J Toxicol Clin Toxicol.</i> 2002;40(4):415-446.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/12216995/pubmed" id="12216995" target="_blank">12216995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12681886">
<a name="12681886"></a>Barnhart KT, Gosman G, Ashby R, Sammel M. The medical management of ectopic pregnancy: a meta-analysis comparing "single dose" and "multidose" regimens. <i>Obstet Gynecol</i>. 2003;101(4):778-784.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/12681886/pubmed" id="12681886" target="_blank">12681886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12637469">
<a name="12637469"></a>Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. <i>J Clin Oncol</i>. 2003;21(6):1044-1049. doi: 10.1200/JCO.2003.03.036.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/12637469/pubmed" id="12637469" target="_blank">12637469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2645044">
<a name="2645044"></a>Bleyer WA. New Vistas for Leucovorin in Cancer Chemotherapy. <i>Cancer.</i> 1989;63(6)(suppl):995-1007. doi: 10.1002/1097-0142(19890315)63:6+&lt;995::aid-cncr2820631302&gt;3.0.co;2-r<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/2645044/pubmed" id="2645044" target="_blank">2645044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-342086">
<a name="342086"></a>Bleyer WA. The clinical pharmacology of methotrexate: new applications of an old drug. <i>Cancer</i>. 1978;41(1):36-51. doi: 10.1002/1097-0142(197801)41:1&lt;36::aid-cncr2820410108&gt;3.0.co;2-i.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/342086/pubmed" id="342086" target="_blank">342086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bleyer.1">
<a name="Bleyer.1"></a>Bleyer WA. Therapeutic monitoring of methotrexate and other antineoplastic drugs. In Baer DM, Devits WR meds. <i>Interpretations in Therapeutic Drug Monitoring</i>. Chicago, IL: American Society of Clinical Pathology; 1981:169-181.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.1">
<a name="Bradley.1"></a>Bradley JS and Nelson JD, eds. <i>Nelson's Pediatric Antimicrobial Therapy</i>. 25th ed. Itasca, IL: American Academy of Pediatrics; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12895397">
<a name="12895397"></a>Briemberg HR, Amato AA. Dermatomyositis and polymyositis. <i>Curr Treat Options Neurol</i>. 2003;5(5):349-356. doi: 10.1007/s11940-003-0025-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/12895397/pubmed" id="12895397" target="_blank">12895397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12177775">
<a name="12177775"></a>Cheeseman SL, Joel SP, Chester JD, et al. A ‘Modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. <i>Br J Cancer.</i> 2002;87(4):393-399. doi: 10.1038/sj.bjc.6600467.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/12177775/pubmed" id="12177775" target="_blank">12177775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cloherty.1">
<a name="Cloherty.1"></a>Cloherty JP, Eichenwald EC, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21561347">
<a name="21561347"></a>Conroy T, Desseigne F, Ychou M, et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. <i>N Engl J Med</i>. 2011;364(19):1817-1825. doi: 10.1056/NEJMoa1011923.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/21561347/pubmed" id="21561347" target="_blank">21561347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575490">
<a name="30575490"></a>Conroy T, Hammel P, Hebbar M, et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. <i>N Engl J Med</i>. 2018;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/30575490/pubmed" id="30575490" target="_blank">30575490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15718320">
<a name="15718320"></a>Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. <i>J Clin Oncol.</i> 2005;23(6):1228-1236. doi: 10.1200/JCO.2005.06.050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/15718320/pubmed" id="15718320" target="_blank">15718320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20940718">
<a name="20940718"></a>Conroy T, Yataghène Y, Etienne PL, et al. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. <i>Br J Cancer</i>. 2010;103(9):1349-1355. doi:10.1038/sj.bjc.6605943<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/20940718/pubmed" id="20940718" target="_blank">20940718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24942828">
<a name="24942828"></a>Devalia V, Hamilton MS, Molloy AM; British Committee for Standards in Haematology. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. <i>Br J Haematol</i>. 2014;166(4):496‐513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/24942828/pubmed" id="24942828" target="_blank">24942828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18021918">
<a name="18021918"></a>Djukic A. Folate-responsive neurologic diseases. <i>Pediatr Neurol</i>. 2007;37(6):387-397.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/18021918/pubmed" id="18021918" target="_blank">18021918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline no. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27813249">
<a name="27813249"></a>Elson CJ, Salim R, Potdar N, Chetty M, Ross JA, Kirk EJ on behalf of the Royal College of Obstetricians and Gynaecologists (RCOG). Diagnosis and management of ectopic pregnancy: Green-top Guideline No. 21. <i>BJOG</i>. 2016;123(13):e15-e55. doi: 10.1111/1471-0528.14189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/27813249/pubmed" id="27813249" target="_blank">27813249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27382098">
<a name="27382098"></a>Enzinger PC, Burtness BA, Niedzwiecki D, et al. CALGB 80403 (Alliance)/E1206: a randomized phase II study of three chemotherapy regimens plus cetuximab in metastatic esophageal and gastroesophageal junction cancers. <i>J Clin Oncol.</i> 2016;34(23):2736-2742. doi:10.1200/JCO.2015.65.5092<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/27382098/pubmed" id="27382098" target="_blank">27382098</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675675">
<a name="14675675"></a>Escobar PF, Lurain JR, Singh DK, Bozorgi K, Fishman DA. Treatment of high-risk gestational trophoblastic neoplasia with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine chemotherapy. <i>Gynecol Oncol</i>. 2003;91(3):552-557. doi: 10.1016/j.ygyno.2003.08.028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/14675675/pubmed" id="14675675" target="_blank">14675675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17470860">
<a name="17470860"></a>Falcone A, Ricci S, Brunetti I, et al; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. <i>J Clin Oncol</i>. 2007;25(13):1670-1676. doi:10.1200/JCO.2006.09.0928<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/17470860/pubmed" id="17470860" target="_blank">17470860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13677584">
<a name="13677584"></a>Frye RE, Donner E, Golja A, Rooney CM. Folinic acid-responsive seizures presenting as breakthrough seizures in a 3-month-old boy. <i>J Child Neurol</i>. 2003;18(8):562-569. doi: 10.1177/08830738030180081001.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/13677584/pubmed" id="13677584" target="_blank">13677584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19142996">
<a name="19142996"></a>Gallagher RC, Van Hove JL, Scharer G, et al. Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy. <i>Ann Neurol</i>. 2009;65(5):550-556. doi: 10.1002/ana.21568.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/19142996/pubmed" id="19142996" target="_blank">19142996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15086738">
<a name="15086738"></a>Ghaemmaghami F, Modares M, Arab M, et al. EMA-EP regimen, as firstline multiple agent chemotherapy in high-risk GTT patients (stage II-IV). <i>Int J Gynecol Cancer</i>. 2004;14(2):360-365. doi: 10.1111/j.1048-891X.2004.014222.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/15086738/pubmed" id="15086738" target="_blank">15086738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10589750">
<a name="10589750"></a>Glantz MJ, Jaeckle KA, Chamberlain MC, et al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. <i>Clin Cancer Res</i>. 1999;5(11):3394-3402.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/10589750/pubmed" id="10589750" target="_blank">10589750</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27022122">
<a name="27022122"></a>Glass J, Won M, Schultz CJ, et al. Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227. <i>J Clin Oncol.</i> 2016;34(14):1620-1625. doi: 10.1200/JCO.2015.64.8634.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/27022122/pubmed" id="27022122" target="_blank">27022122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21502557">
<a name="21502557"></a>Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. <i>J Clin Oncol.</i> 2011;29(16):2171-2177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/21502557/pubmed" id="21502557" target="_blank">21502557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25287828">
<a name="25287828"></a>Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. <i>J Clin Oncol.</i> 2014;32(31):3520-3526.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/25287828/pubmed" id="25287828" target="_blank">25287828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16314627">
<a name="16314627"></a>Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.<i> J Clin Oncol</i>. 2005;23(34):8671-8678. doi: 10.1200/JCO.2004.00.5686.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/16314627/pubmed" id="16314627" target="_blank">16314627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15781200">
<a name="15781200"></a>Hansen FJ, Blau N. Cerebral folate deficiency: life-changing supplementation with folinic acid. <i>Mol Genet Metab</i>. 2005;84(4):371‐373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/15781200/pubmed" id="15781200" target="_blank">15781200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24608198">
<a name="24608198"></a>Hochster HS, Grothey A, Hart L, et al. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. <i>Ann Oncol.</i> 2014;25(6):1172-1178. doi:10.1093/annonc/mdu107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/24608198/pubmed" id="24608198" target="_blank">24608198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7564240">
<a name="7564240"></a>Hyland K, Buist NR, Powell BR, et al. Folinic acid responsive seizures: a new syndrome?. <i>J Inherit Metab Dis</i>. 1995;18(2):177‐181.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/7564240/pubmed" id="7564240" target="_blank">7564240</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3537623">
<a name="3537623"></a>Jacobsen D, McMartin KE. Methanol and ethylene glycol poisonings. Mechanism of toxicity, clinical course, diagnosis and treatment. <i>Med Toxicol. </i>1986;1(5):309-334. doi: 10.1007/bf03259846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/3537623/pubmed" id="3537623" target="_blank">3537623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34102137">
<a name="34102137"></a>Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. <i>Lancet</i>. 2021;398(10294):27-40. doi:10.1016/S0140-6736(21)00797-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/34102137/pubmed" id="34102137" target="_blank">34102137</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8689347">
<a name="8689347"></a>Jardine LF, Ingram LC, Bleyer WA. Intrathecal leucovorin after intrathecal methotrexate overdose. <i>J Pediatr Hematol Oncol.</i> 1996;18(3):302-304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/8689347/pubmed" id="8689347" target="_blank">8689347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15481055">
<a name="15481055"></a>Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. <i>Cancer</i>. 2004;101(12):2788-2801. doi: 10.1002/cncr.20668.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/15481055/pubmed" id="15481055" target="_blank">15481055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180816">
<a name="31180816"></a>Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update.<i> J Clin Oncol</i>. 2019;37(23):2082-2088. doi: 10.1200/JCO.19.00946.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/31180816/pubmed" id="31180816" target="_blank">31180816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9850025">
<a name="9850025"></a>Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. <i>J Clin Oncol</i>. 1998;16(12):3803-3809. doi: 10.1200/JCO.1998.16.12.3803.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/9850025/pubmed" id="9850025" target="_blank">9850025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM and St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Philadelphia, PA: Saunders Elsevier; 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21275495">
<a name="21275495"></a>Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/21275495/pubmed" id="21275495" target="_blank">21275495</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12727579">
<a name="12727579"></a>Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. <i>Am J Med</i>. 2003;114(6):463-469. doi: 10.1016/s0002-9343(03)00077-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/12727579/pubmed" id="12727579" target="_blank">12727579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lederle.1">
<a name="Lederle.1"></a>Lederle Leucovorin (calcium folinate) tablets, USP [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada ULC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leucovorin.1">
<a name="Leucovorin.1"></a>Leucovorin calcium for injection [prescribing information]. Lake Zurich, IL: Fresenius Kabi; April 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leucovorin.2">
<a name="Leucovorin.2"></a>Leucovorin calcium for injection [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA Inc: October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leucovorin.3">
<a name="Leucovorin.3"></a>Leucovorin calcium injection [product monograph]. Toronto, Ontario, Canada: Generic Medical Partners Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leucovorin.4">
<a name="Leucovorin.4"></a>Leucovorin calcium tablets [prescribing information]. Laurelton, NY: Epic Pharma, LLC; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leucovorin.5">
<a name="Leucovorin.5"></a>Leucovorin calcium tablets [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17086804">
<a name="17086804"></a>Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. <i>J Reprod Med</i>. 2006;51(10):767-772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/17086804/pubmed" id="17086804" target="_blank">17086804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9317168">
<a name="9317168"></a>Machover D. A Comprehensive Review of 5-Fluorouracil and Leucovorin in Patients With Metastatic Colorectal Carcinoma. <i>Cancer.</i> 1997;80(7):1179-1187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/9317168/pubmed" id="9317168" target="_blank">9317168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10658524">
<a name="10658524"></a>Maindrault-Goebel F, Louvet C, André T, et al. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR.<i> Eur J Cancer</i>. 1999;35(9):1338-1342. doi: 10.1016/s0959-8049(99)00149-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/10658524/pubmed" id="10658524" target="_blank">10658524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18227714">
<a name="18227714"></a>McAuley JB. Toxoplasmosis in children. <i>Pediatr Infect Dis J</i>. 2008;27(2):161-162.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/18227714/pubmed" id="18227714" target="_blank">18227714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3257913">
<a name="3257913"></a>McGuire BW, Sia LL, Leese PT, et al, “Pharmacokinetics of Leucovorin Calcium After Intravenous, Intramuscular, and Oral Administration,” <i>Clin Pharm</i>, 1988, 7(1):52-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/3257913/pubmed" id="3257913" target="_blank">3257913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18612102">
<a name="18612102"></a>Mead GM, Barrans SL, Qian W, et al; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i>. 2008;112(6):2248-2260. doi: 10.1182/blood-2008-03-145128.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/18612102/pubmed" id="18612102" target="_blank">18612102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.2019">
<a name="Miller.2019"></a>Miller ML. Initial treatment of dermatomyositis and polymyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1">
<a name="Nelson.1"></a>Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10673528">
<a name="10673528"></a>Newlands ES, Mulholland PJ, Holden L, Seckl MJ, Rustin GJ. Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. <i>J Clin Oncol</i>. 2000;18(4):854-859. doi: 10.1200/JCO.2000.18.4.854.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/10673528/pubmed" id="10673528" target="_blank">10673528</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16458834">
<a name="16458834"></a>Nicolai J, van Kranen-Mastenbroek VH, Wevers RA, Hurkx WA, Vles JS. Folinic acid-responsive seizures initially responsive to pyridoxine. <i>Pediatr Neurol</i>. 2006;34(2):164-167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/16458834/pubmed" id="16458834" target="_blank">16458834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24982456">
<a name="24982456"></a>Oettle H, Riess H, Stieler JM, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. <i>J Clin Oncol</i>. 2014;32(23):2423-2429. doi: 10.1200/JCO.2013.53.6995.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/24982456/pubmed" id="24982456" target="_blank">24982456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2940870">
<a name="2940870"></a>Ory SJ, Villanueva AL, Sand PK, Tamura RK. Conservative treatment of ectopic pregnancy with methotrexate. <i>Am J Obstet Gynecol</i>. 1986;154(6):1299-1306.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/2940870/pubmed" id="2940870" target="_blank">2940870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19109574">
<a name="19109574"></a>Pagnoux C, Mahr A, Hamidou MA, et al; French Vasculitis Study Group. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. <i>N Engl J Med</i>. 2008;359(26):2790-2803. doi: 10.1056/NEJMoa0802311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/19109574/pubmed" id="19109574" target="_blank">19109574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21565490">
<a name="21565490"></a>Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. <i>Eur J Cancer</i>. 2011;47(11):1676-1681. doi: 10.1016/j.ejca.2011.04.011.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/21565490/pubmed" id="21565490" target="_blank">21565490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23849842">
<a name="23849842"></a>Practice Committee of American Society for Reproductive Medicine (ASRM). Medical treatment of ectopic pregnancy: a committee opinion. <i>Fertil Steril</i>. 2013;100(3):638-644. doi: 10.1016/j.fertnstert.2013.06.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/23849842/pubmed" id="23849842" target="_blank">23849842</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15581159">
<a name="15581159"></a>Ramaekers VT, Blau N. Cerebral folate deficiency. <i>Dev Med Child Neurol</i>. 2004;46(12):843‐851.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/15581159/pubmed" id="15581159" target="_blank">15581159</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12571785">
<a name="12571785"></a>Ramaekers VT, Häusler M, Opladen T, Heimann G, Blau N. Psychomotor retardation, spastic paraplegia, cerebellar ataxia and dyskinesia associated with low 5-methyltetrahydrofolate in cerebrospinal fluid: a novel neurometabolic condition responding to folinic acid substitution. <i>Neuropediatrics</i>. 2002;33(6):301‐308.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/12571785/pubmed" id="12571785" target="_blank">12571785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29079637">
<a name="29079637"></a>Ramsey LB, Balis FM, O’Brien MM, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance. <i>Oncologist.</i> 2018.23(1):52-61. doi: 10.1634/theoncologist.2017-0243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/29079637/pubmed" id="29079637" target="_blank">29079637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23569323">
<a name="23569323"></a>Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). <i>J Clin Oncol.</i> 2013;31(25):3061-3068. doi: 10.1200/JCO.2012.46.9957.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/23569323/pubmed" id="23569323" target="_blank">23569323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1832538">
<a name="1832538"></a>Rustum YM. Modulation of Fluoropyrimidines by Leucovorin: Rationale and Status. <i>J Surg Oncol Suppl. </i>1991;2:116-123.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/1832538/pubmed" id="1832538" target="_blank">1832538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23892326">
<a name="23892326"></a>Ruutu T, Gratwohl A, de Witte T, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. <i>Bone Marrow Transplant</i>. 2013;49(2):168-173. doi: 10.1038/bmt.2013.107.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/23892326/pubmed" id="23892326" target="_blank">23892326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2444463">
<a name="2444463"></a>Sauer MV, Gorrill MJ, Rodi IA, et al. Nonsurgical management of unruptured ectopic pregnancy: an extended clinical trial. <i>Fertil Steril</i>. 1987;48(5):752-725.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/2444463/pubmed" id="2444463" target="_blank">2444463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17947720">
<a name="17947720"></a>Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. <i>J Clin Oncol</i>. 2007;25(30):4730-4735. doi: 10.1200/JCO.2007.12.5062.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/17947720/pubmed" id="17947720" target="_blank">17947720</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26438119">
<a name="26438119"></a>Shah MA, Janjigian YY, Stoller R, et al. Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium. <i>J Clin Oncol</i>. 2015;33(33):3874-3879. doi:10.1200/JCO.2015.60.7465<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/26438119/pubmed" id="26438119" target="_blank">26438119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32568633">
<a name="32568633"></a>Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. <i>J Clin Oncol.</i> 2020;38(23):2677-2694. doi:10.1200/JCO.20.00866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/32568633/pubmed" id="32568633" target="_blank">32568633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18570175">
<a name="18570175"></a>Smith SW, Nelson LS. Case files of the New York City Poison Control Center: antidotal strategies for the management of methotrexate toxicity. <i>J Med Toxicol.</i> 2008;4(2):132-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/18570175/pubmed" id="18570175" target="_blank">18570175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32755482">
<a name="32755482"></a>Sohal DPS, Kennedy EB, Cinar P, et al. Metastatic pancreatic cancer: ASCO guideline update. <i>J Clin Oncol</i>. Published online August 5, 2020. doi:10.1200/JCO.20.01364<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/32755482/pubmed" id="32755482" target="_blank">32755482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2784113">
<a name="2784113"></a>Stovall TG, Ling FW, Buster JE. Outpatient chemotherapy of unruptured ectopic pregnancy. <i>Fertil Steril</i>. 1989;51(3):435-438.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/2784113/pubmed" id="2784113" target="_blank">2784113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2014091">
<a name="2014091"></a>Stovall TG, Ling FW, Gray LA. Single-dose methotrexate for treatment of ectopic pregnancy. <i>Obstet Gynecol</i>. 1991;77(5):754-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/2014091/pubmed" id="2014091" target="_blank">2014091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14551133">
<a name="14551133"></a>Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i>. 2004;103(12):4396-4407. doi: 10.1182/blood-2003-08-2958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/14551133/pubmed" id="14551133" target="_blank">14551133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502413">
<a name="16502413"></a>Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i>. 2006;106(7):1569-1580. doi: 10.1002/cncr.21776.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/16502413/pubmed" id="16502413" target="_blank">16502413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10456764">
<a name="10456764"></a>Torres OA, Miller VS, Buist NM, Hyland K. Folinic acid-responsive neonatal seizures. <i>J Child Neurol</i>. 1999;14(8):529-532.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/10456764/pubmed" id="10456764" target="_blank">10456764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7627739">
<a name="7627739"></a>Trissel LA, Martinez JF, Xu QA. Incompatibility of fluorouracil with leucovorin calcium or levoleucovorin calcium. <i>Am J Health Syst Pharm.</i> 1995;52(7):710-715.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/7627739/pubmed" id="7627739" target="_blank">7627739</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25457996">
<a name="25457996"></a>Ureña-Tavera A, Zamora-Verduga M, Madrigal-Burgaleta R, Angel-Pereira D, Berges-Gimeno MP, Alvarez-Cuesta E. Hypersensitivity reactions to racemic calcium folinate (leucovorin) during FOLFOX and FOLFIRI chemotherapy administrations.<i> J Allergy Clin Immunol.</i> 2015;135(4):1066-1067.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/25457996/pubmed" id="25457996" target="_blank">25457996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf</a>. Updated December 2019. Accessed June 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2">
<a name="HHS.2"></a>US Department of Health and Human Services (HHS) Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/pediatric-arv/guidelines-pediatric-arv.pdf</a>. Updated April 2020. Accessed June 2, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.3">
<a name="HHS.3"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Accessed May 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8627092">
<a name="8627092"></a>Van Delden C, Hirschel B. Folinic acid supplements to pyrimethamine-sulfadiazine for <i>Toxoplasma encephalitis</i> are associated with better outcome. <i>J Infect Dis</i>, 1996, 173(5):1294-1295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/8627092/pubmed" id="8627092" target="_blank">8627092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Walker.1">
<a name="Walker.1"></a>Walker SE, Law S, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. <i>Can J Hosp Pharm.</i> 2005;58(4):212-222.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16794248">
<a name="16794248"></a>Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. <i>Oncologist.</i> 2006;11(6):694-703.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/16794248/pubmed" id="16794248" target="_blank">16794248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22481063">
<a name="22481063"></a>Xiang XJ, Liu YW, Zhang L, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. <i>Anticancer Drugs</i>. 2012;23(5):561-566. doi:10.1097/CAD.0b013e328350dd0d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/22481063/pubmed" id="22481063" target="_blank">22481063</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34656226">
<a name="34656226"></a>Yoo C, Kim KP, Jeong JH, et al. Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. <i>Lancet Oncol</i>. 2021;22(11):1560-1572. doi:10.1016/S1470-2045(21)00486-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/34656226/pubmed" id="34656226" target="_blank">34656226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20223786">
<a name="20223786"></a>Zaanan A, Costes L, Gauthier M, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. <i>Ann Oncol</i>. 2010;21(9):1786-1793. doi:10.1093/annonc/mdq038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/20223786/pubmed" id="20223786" target="_blank">20223786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21425142">
<a name="21425142"></a>Zaanan A, Gauthier M, Malka D, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. <i>Cancer.</i> 2011;117(7):1422-1428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/leucovorin-pediatric-drug-information/abstract-text/21425142/pubmed" id="21425142" target="_blank">21425142</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12544 Version 294.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
